Core Insights - Capricor Therapeutics is advancing its lead product candidate, Deramiocel, for Duchenne muscular dystrophy (DMD) with a Biologics License Application (BLA) currently under FDA review, targeting a decision date of August 22, 2026 [2][5] - The company reported significant financial results for the fourth quarter and full year of 2025, including a cash balance of approximately $318 million, which is expected to support operations through 2027 [7][11] Regulatory and Clinical Updates - The FDA is reviewing Capricor's BLA for Deramiocel, classified as a Class 2 resubmission, with the company focusing on execution and preparation for a potential launch [5][6] - The pivotal HOPE-3 Phase 3 trial met its primary endpoint and key secondary cardiac endpoint, demonstrating statistical significance [4][5] - Late-breaking data from the HOPE-3 trial presented at the 2026 MDA Conference highlighted Deramiocel's benefits on cardiac function and disease progression [4][5] Financial Performance - Capricor reported no revenues for the fourth quarter and full year of 2025, a decrease from $11.1 million and $22.3 million in the respective periods of 2024 [8] - Total operating expenses for Q4 2025 were approximately $29.2 million, up from $18.8 million in Q4 2024, with total operating expenses for the year reaching approximately $108.1 million [9] - The net loss for Q4 2025 was approximately $30.2 million, or $0.62 per share, compared to a net loss of $7.1 million, or $0.16 per share, in Q4 2024 [10] Corporate Developments - Capricor's GMP manufacturing facility in San Diego is operational and has completed an FDA Pre-License Inspection, positioning the company for a potential commercial launch [6][4] - The company successfully uplisted to the Nasdaq Global Select Market, enhancing its visibility and access to capital [4][14] - Capricor's balance sheet was strengthened by a public offering that generated approximately $161.9 million in net proceeds [14][7]

Core Insights - Capricor Therapeutics announced new data from the Phase 3 HOPE-3 clinical trial of Deramiocel for Duchenne muscular dystrophy (DMD), highlighting its potential impact on patients' daily lives and long-term outcomes [1][3][5] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead product candidate currently in late-stage development for DMD [10] - The company has received multiple designations for Deramiocel, including Orphan Drug Designation from the U.S. FDA and EMA, and Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. [9] Clinical Trial Results - The HOPE-3 trial results showed a significant reduction in myocardial fibrosis measured by late gadolinium enhancement (LGE) on cardiac MRI (p=0.022) [6] - In patients with baseline cardiomyopathy, Deramiocel demonstrated a 3.3 percentage-point improvement in left ventricular ejection fraction (LVEF) versus placebo (p=0.017) [6] - The Global Statistical Test (GST) composite endpoint indicated a statistically significant overall treatment benefit favoring Deramiocel (p=0.017) [6] - The Duchenne Video Assessment (DVA) showed approximately 83% slowing of disease progression compared to placebo (p=0.018) [6] Regulatory Status - The Biologics License Application (BLA) for Deramiocel is currently under FDA review, with a target action date of August 22, 2026 [3][5] Collaboration and Commercialization - Capricor has entered into an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan, pending regulatory approval [12]

Core Viewpoint - Capricor Therapeutics has received FDA approval to resume the review of its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD), with a target action date set for August 22, 2026 [1][2][8] Company Overview - Capricor Therapeutics is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead product candidate [9] - The company aims to redefine treatment options for DMD, which affects approximately 15,000 individuals in the U.S., primarily boys [4][9] Product Details - Deramiocel (CAP-1002) is an allogeneic cardiac-derived cell therapy that has shown immunomodulatory and anti-fibrotic effects in preserving muscle function in DMD [5][9] - The therapy has received multiple designations, including Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which may qualify the company for a Priority Review Voucher upon approval [6][8] Clinical Development - The FDA's resumption of the BLA review follows the submission of data from the HOPE-3 clinical trial, which demonstrated positive results, including achievement of primary and secondary endpoints [2][8] - The company has administered Deramiocel to over 250 human subjects across multiple clinical trials, supported by extensive preclinical and clinical data [5][9] Regulatory Milestones - The FDA issued a Complete Response Letter in July 2025, which has now been lifted, allowing the review process to continue without identified issues [2][8] - The Prescription Drug User Fee Act (PDUFA) target action date for the BLA is set for August 22, 2026 [1][2][8] Commercialization Strategy - Capricor has entered into an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of Deramiocel in the U.S. and Japan, pending regulatory approval [11]

Core Insights - Capricor Therapeutics has published a study on Deramiocel's anti-fibrotic activity, highlighting a validated potency assay that supports quality control in late-stage development for Duchenne muscular dystrophy (DMD) [1][4] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapies for rare diseases, with Deramiocel as its lead investigational product [1][10] - The company has received multiple designations for Deramiocel, including Orphan Drug Designation from the U.S. FDA and EMA, and Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. [7] Research Findings - The publication details a novel in-vitro potency assay that characterizes the anti-fibrotic mechanism of action of cardiosphere-derived cells (CDCs) in Deramiocel, showing that CDCs can suppress collagen I and III gene expression in human fibroblasts [2][3] - Consistent findings across over one hundred manufacturing lots of Deramiocel demonstrate its anti-fibrotic mechanism, aligning with in vivo studies and clinical data showing stabilization of cardiac function in DMD patients [3] Clinical Development - Deramiocel is currently being evaluated in the Phase 3 HOPE-3 trial, with topline data expected in mid-fourth quarter of 2025 [4][8] - The HOPE-3 trial is a multi-center, randomized, double-blind, placebo-controlled study involving 105 eligible subjects [8][9] Mechanism of Action - Deramiocel consists of allogeneic CDCs that exert immunomodulatory and anti-fibrotic actions, preserving cardiac and skeletal muscle function in muscular dystrophies [6][10] - CDCs secrete exosomes that target macrophages, promoting a healing phenotype rather than a pro-inflammatory one [6] Educational Initiatives - To complement the publication, Capricor has released an educational video explaining the mechanism of action of Deramiocel [5]

Core Insights - Capricor Therapeutics is focused on developing therapies for Duchenne cardiomyopathy and has faced regulatory challenges but is working on a clear path forward for approval [2][4] - The company has made significant progress with its exosome platform, StealthX™, which has received FDA clearance for clinical trials [4][6] - Financial results indicate a net loss for the second quarter of 2025, with revenues dropping to zero compared to the previous year [8][10] Corporate Update - Capricor aims to resubmit its Biologics License Application (BLA) for Deramiocel based on existing data, with additional data from the HOPE-3 trial expected in Q4 2025 [4][5] - The FDA has accepted all observations from the Pre-License Inspection, marking a milestone in regulatory progress [4][5] - The company is preparing for a Type A meeting with the FDA to discuss the approval pathway [4][5] Financial Performance - Cash position as of June 30, 2025, was approximately $122.8 million, down from $151.5 million at the end of 2024 [7][26] - Revenues for Q2 2025 were $0, a decrease from approximately $4.0 million in Q2 2024, and for the first half of 2025, revenues were also $0 compared to approximately $8.9 million in the first half of 2024 [8][10] - Total operating expenses for Q2 2025 were approximately $27.7 million, up from $15.6 million in Q2 2024 [9][10] Clinical Development - The HOPE-3 Phase 3 clinical trial is ongoing, with topline data expected in Q4 2025 [5][6] - The FDA has cleared the IND for the StealthX™ exosome-based vaccine, marking its first clinical entry [4][6] - Orphan Drug Designation has been granted for Deramiocel in Becker muscular dystrophy, expanding its therapeutic strategy [5][6]

Core Insights - Capricor Therapeutics is hosting a webinar on July 29, 2025, to discuss the status of its Biologics License Application (BLA) for Deramiocel and provide information on cardiomyopathy in Duchenne Muscular Dystrophy (DMD) [1][2] - Deramiocel is an allogeneic cardiac-derived cell therapy currently in late-stage development for DMD, demonstrating potent immunomodulatory and anti-fibrotic actions [3][5] - Capricor has entered an exclusive commercialization agreement for Deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [5] Company Overview - Capricor Therapeutics focuses on developing cell and exosome-based therapeutics for rare diseases, with a commitment to innovative treatments [3] - The company utilizes its proprietary StealthX™ platform for preclinical development in various therapeutic areas, including vaccinology and targeted delivery [3] Webinar Details - The webinar will include a review of the BLA status for Deramiocel and a Q&A session with the community [1] - A replay of the webinar will be available on the Parent Project Muscular Dystrophy (PPMD) website [2]

Core Insights - Capricor Therapeutics is making significant progress towards delivering the first approved therapy for Duchenne cardiomyopathy, with an FDA target action date of August 31, 2025 for their Biologics License Application (BLA) [2][4][5] Financial Results - As of March 31, 2025, Capricor reported a cash position of approximately $145 million, down from $151.5 million at the end of 2024 [6][9] - Revenues for the first quarter of 2025 were $0, a decrease from $4.9 million in the same quarter of 2024, primarily due to the recognition of previous milestone payments [7] - Total operating expenses for Q1 2025 were approximately $25 million, compared to $15.2 million in Q1 2024, leading to a net loss of approximately $24.4 million, or $0.53 per share, compared to a net loss of $9.8 million, or $0.31 per share, in Q1 2024 [8][20] Corporate Developments - The FDA has accepted Capricor's BLA for deramiocel, which is under priority review, with no significant deficiencies identified in the recent mid-cycle review [4][5] - Capricor appointed Dr. Michael Binks as Chief Medical Officer, who brings over 25 years of experience in clinical development [5] - The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate a Phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in Q3 2025, pending regulatory approval [5][12] Upcoming Milestones - Capricor is preparing for an FDA advisory committee meeting and a pre-approval inspection as part of the BLA process [2][4] - The company expects its cash reserves to support operations into 2027, excluding additional potential milestone payments [9]

Core Viewpoint - Capricor Therapeutics is set to release its financial results for the first quarter of 2025 on May 13, 2025, followed by a conference call to discuss the results and recent corporate updates [1][2]. Company Overview - Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, with its lead product candidate being deramiocel, a cardiac-derived cell therapy [3]. - Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD) and has shown significant immunomodulatory and anti-fibrotic effects in preclinical and clinical studies [3]. - The company is also utilizing its proprietary StealthX™ platform for the preclinical development of exosome technology aimed at various therapeutic applications, including vaccinology and targeted delivery of therapeutics [3]. Recent Developments - Capricor has entered into an exclusive commercialization and distribution agreement for deramiocel in the United States and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [6].